Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility
BRAFi/MEKi-induced cardiotoxicity is a significant but manageable complication, often reversible with timely interventions. Routine LVEF monitoring is recommended. The majority (92%) of major cardiac events were diagnosed within the first year of treatment, which might warrant a discontinuation of routine LVEF monitoring after 1 year of BRAFi/MEKi treatment.
Authors
- I. Meklenborg
- Louise Mahncke Guldbrandt
- Rasmus Blechingberg Friis (ORCID: https://orcid.org/0000-0002-0564-146X)
- Lars Bastholt (ORCID: https://orcid.org/0000-0001-5478-9826)
- Henrik Schmidt (ORCID: https://orcid.org/0000-0002-4063-3561)
- Jonas K Oddershede
Institutions
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-04-13
- DOI
- https://doi.org/10.2340/1651-226x.2025.42567
- Citations
- 7
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- Aarhus Universitet
- Aarhus Universitetshospital